Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;89(3):275-84.
doi: 10.1111/cge.12654. Epub 2015 Sep 22.

Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care

Affiliations
Review

Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care

S L Sawyer et al. Clin Genet. 2016 Mar.

Abstract

An accurate diagnosis is an integral component of patient care for children with rare genetic disease. Recent advances in sequencing, in particular whole-exome sequencing (WES), are identifying the genetic basis of disease for 25-40% of patients. The diagnostic rate is probably influenced by when in the diagnostic process WES is used. The Finding Of Rare Disease GEnes (FORGE) Canada project was a nation-wide effort to identify mutations for childhood-onset disorders using WES. Most children enrolled in the FORGE project were toward the end of the diagnostic odyssey. The two primary outcomes of FORGE were novel gene discovery and the identification of mutations in genes known to cause disease. In the latter instance, WES identified mutations in known disease genes for 105 of 362 families studied (29%), thereby informing the impact of WES in the setting of the diagnostic odyssey. Our analysis of this dataset showed that these known disease genes were not identified prior to WES enrollment for two key reasons: genetic heterogeneity associated with a clinical diagnosis and atypical presentation of known, clinically recognized diseases. What is becoming increasingly clear is that WES will be paradigm altering for patients and families with rare genetic diseases.

Keywords: FORGE Canada Consortium; clinical exome; rare diseases; whole-exome sequencing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Outcomes of the 362 families studied using whole‐exome sequencing (WES) as part of the Finding Of Rare Disease GEnes (FORGE) Canada research study. Overall, 188 of the 362 (51.9%) families received a definitive molecular diagnosis, either in a gene previously known to cause a similar disease (known) or in a gene that had not been previously associated with the family's disease (novel). Of the 174 (48.1%) of families that remain unsolved, 28 have single‐surviving candidates for which we are gathering additional evidence to support pathogenicity.

References

    1. Orphanet. Prevalence of rare diseases: Bibliographic data. Orphanet Reports Series 2014; Rare Diseases collection.
    1. McKusick VA. Mendelian Inheritance in Man and its online version, OMIM. Am J Hum Genet 2007: 80: 588–604. - PMC - PubMed
    1. Shashi V, McConkie‐Rosell A, Rosell B et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next‐generation sequencing for undiagnosed genetic disorders. Genet Med 2014: 16: 176–182. - PubMed
    1. Graungaard AH, Skov L. Why do we need a diagnosis? A qualitative study of parents' experiences, coping and needs, when the newborn child is severely disabled. Child Care Health Dev 2007: 33: 296–307. - PubMed
    1. Eurordis. EurordisCare2: survey of diagnostic delays, 8 diseases, Europe.